Table 2

Patients’ and healthy controls’ characteristics
Whole group RR PP + SP Healthy controls
(n=414) (n=273) (n=141) (n=414)
female/male 264/150 179/94 85/56 264/150
♀ (%) (63.77 %) (65.56%) (60.3%) (63.77 %)
Age, yy ± SD 42.0±11.0 38.5±9.51 48.5±10.40* 42.0±11.0
(range) (16.0-72.0) (17.0-70.0) (16.0-72.0) (16.0-72.0)
onset, yy ± SD 32.37±10.37 31.65±10.31 33.17±10.21 -- --
(range) (11.0-61.0) (14.0-61.0) (11.0-55.0)
Duration, yy ± SD 9.14±7.43 6.92±6.47 13.44±7.34* -- --
(range) (0.2-50.0) (0.2-50.0) (0.2-35.0)
EDSS ± SD 2.91±2.24 1.8±1.04 5.03±2.43* -- --
(range) (1.0-10.0) (1.0-7.0) (1.0-10.0)
PI ± SD 0.63±1.08 0.59±0.94 0.72±1.32* -- --
(range) (0.03-10.0) (0.03-10.0) (0.04-10.0)
MSSS ± SD 3.94±2.74 2.93±1.99 5.98±2.87* -- --
(range) (0.13-9.99) (0.13-9.6) (0.29-9.99)

*P<0.0001, when compared to the RR group. Values shown are mean, standard deviation (SD), and (ranges).

Gemmati et al.

Gemmati et al. BMC Medical Genetics 2012 13:70   doi:10.1186/1471-2350-13-70

Open Data